Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | CEL | P19835 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13464692 | 1.00 | HDAC3 (0.44) | HDAC3HDAC1HDAC2TAAR1HTR2A | |
| SCHEMBL17070215 | 1.00 | HDAC3 (0.44) | HDAC3HDAC1HDAC2TAAR1HTR2A | |
| SCHEMBL11560195 | 0.90 | TAAR1 (0.48) | TAAR1HTR2A | |
| SCHEMBL31327373 | 0.82 | TAAR1 (0.42) | HDAC3HDAC1HDAC2TAAR1HTR2A | |
| SCHEMBL8857684 | 0.82 | MAOB (0.46) | TAAR1HTR2AKMT2AMEN1 | |
| SCHEMBL8857692 | 0.82 | MAOB (0.46) | TAAR1HTR2AKMT2AMEN1 | |
| SCHEMBL9183884 | 0.82 | TAAR1 (0.42) | TAAR1HTR2A | |
| SCHEMBL23506821 | 0.81 | TAAR1 (0.41) | HDAC3HDAC1HDAC2TAAR1HTR2A | |
| SCHEMBL20015576 | 0.81 | HRH3 (0.44) | TAAR1HTR2A | |
| SCHEMBL10479962 | 0.81 | MAOB (0.45) | TAAR1HTR2AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795315-B2 | Group 5 metal complexes for producing amine-functionalized polyolefins | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-10-24 | — | — | US | disclosed |
| US-20200255457-A1 | PROCESS FOR THE REMOVAL AND RETURN OF A CATALYST TO A LIQUID PHASE MEDIUM | PHOSPHONICS LTD (GB) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255457-A1 | PROCESS FOR THE REMOVAL AND RETURN OF A CATALYST TO A LIQUID PHASE MEDIUM | MSR1, NOC2L, GFRA2 | HDAC3 3490/4885HDAC1 3465/4885HDAC2 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.